Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 8/20 | 0.44 |
| ▸ | NCK1 | P16333 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.41 |
| ▸ | NCF1 | P14598 | 7/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119356 | 1.00 | PLAU (0.52) | PLAUBACE1NCK1TLR9NCF1 | |
| SCHEMBL15885419 | 0.83 | ALDH1A1 (0.42) | PLAUBACE1TLR9PDPK1EGFR | |
| SCHEMBL14791619 | 0.83 | PLAU (0.52) | PLAUTLR9PDPK1EGFRKMT2A | |
| SCHEMBL1932280 | 0.79 | BACE1 (0.57) | PLAUBACE1NCK1NCF1NOS2 | |
| SCHEMBL15690411 | 0.79 | BACE1 (0.55) | PLAUBACE1NCK1NCF1NOS2 | |
| SCHEMBL10692301 | 0.79 | BACE1 (0.49) | PLAUBACE1NCK1NCF1NOS2 | |
| SCHEMBL28953346 | 0.75 | PLAU (0.44) | PLAUBACE1NCK1NCF1 | |
| SCHEMBL622192 | 0.75 | PIK3CA (0.42) | TLR9NCF1NOS2PDPK1EGFR | |
| SCHEMBL24506866 | 0.75 | BACE1 (0.42) | PLAUBACE1NCK1NCF1NOS2 | |
| SCHEMBL15690528 | 0.75 | HTT (0.44) | PLAUBACE1NCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9057105-B2 | Method for detecting single nucleotide polymorphism in nucleic acid | FURUKAWA ELECTRIC ADVANCED ENGINEERING CO., LTD. (JP) | 2015-06-16 | — | — | US | claimed |
| US-8911947-B2 | DNA fragment used as attached to 5′ end of primer used in nucleic acid amplification reaction and use of DNA fragment | FURUKAWA ELECTRIC ADVANCED ENGINEERING CO., LTD. (JP) | 2014-12-16 | — | — | US | claimed |
| US-20140255938-A1 | METHOD FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISM IN NUCLEIC ACID | OSAKA UNIVERSITY (JP) | 2014-09-11 | — | — | US | claimed |
| EP-2058392-B1 | DNA FRAGMENT USED IN THE FORM ATTACHED TO 5'-TERMINUS OF PRIMER FOR USE IN AMPLIFICATION REACTION OF NUCLEIC ACID, AND USE THEREOF | UNIV OSAKA (JP) | 2011-10-12 | — | — | EP | claimed |
| US-20100015618-A1 | DNA FRAGMENT USED AS ATTACHED TO 5' END OF PRIMER USED IN NUCLEIC ACID AMPLIFICATION REACTION AND USE OF DNA FRAGMENT | OSAKA UNIVERSITY (JP) | 2010-01-21 | — | — | US | claimed |
| EP-2058392-A1 | DNA FRAGMENT USED IN THE FORM ATTACHED TO 5'-TERMINUS OF PRIMER FOR USE IN AMPLIFICATION REACTION OF NUCLEIC ACID, AND USE THEREOF | Osaka University (JP) | 2009-05-13 | — | — | EP | claimed |
| CN-104903320-B | Nitrogen-containing heterocycle compound or its salt | 富士胶片株式会社 | 2018-11-13 | — | — | CN | disclosed |
| EP-3184636-B1 | PCR METHOD AND PCR KIT | UNIV OSAKA (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20170268042-A1 | PCR METHOD AND PCR KIT | OSAKA UNIVERSITY (JP) | 2017-09-21 | — | — | US | disclosed |
| EP-3184636-A1 | PCR METHOD AND PCR KIT | Osaka University (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9057105-B2 | Method for detecting single nucleotide polymorphism in nucleic acid | FURUKAWA ELECTRIC ADVANCED ENGINEERING CO., LTD. (JP) | 2015-06-16 | — | — | US | disclosed |
| US-8911947-B2 | DNA fragment used as attached to 5′ end of primer used in nucleic acid amplification reaction and use of DNA fragment | FURUKAWA ELECTRIC ADVANCED ENGINEERING CO., LTD. (JP) | 2014-12-16 | — | — | US | disclosed |
| US-20140255938-A1 | METHOD FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISM IN NUCLEIC ACID | OSAKA UNIVERSITY (JP) | 2014-09-11 | — | — | US | disclosed |
| JP-2004262827-A | BULGE BASE RECOGNITION MOLECULE AND METHOD FOR BULGE BASE DETECTION | JAPAN SCIENCE & TECHNOLOGY AGENCY | 2004-09-24 | — | — | JP | disclosed |
| CN-1425014-A | Triazatrinaphthyrins and use thereof | TRINAPCO LLC (US) | 2003-06-18 | — | — | CN | disclosed |
| EP-1244665-A1 | TRIAZATRINAPHTHYRINS AND THE USE THEREOF | Trinapco LLC (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020077473-A1 | TRIAZATRINAPHTHYRINS AND THE USE THEREOF | TRINAPCO, INC. | 2002-06-20 | — | — | US | disclosed |
| US-6407089-B1 | USEFUL IN EXTRACTION OF TRANSITION METALS, IN PARTICULAR IN THE EXTRACTION OF LANTHANIDES | TRINAPCO INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2001046193-A1 | TRIAZATRINAPHTHYRINS AND THE USE THEREOF | TRINAPCO LLC (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-0790997-A2 | 6-ARYL PYRIDO( 2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1997-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077473-A1 | TRIAZATRINAPHTHYRINS AND THE USE THEREOF | TRRAP, TRHR, LBR | PLAU 3443/4885BACE1 4783/4885NCK1 4647/4885 |
| US-20100015618-A1 | DNA FRAGMENT USED AS ATTACHED TO 5' END OF PRIMER USED IN NUCLEIC ACID AMPLIFICATION REACTION AND USE OF DNA FRAGMENT | PCNA, APEX1, RNGTT | PLAU 3432/4885BACE1 3232/4885NCK1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.